Holen Sie sich die Stockscreener-App
8.909
32.83%
2.239
Handel nachbörslich:
8.89
-0.019
-0.21%
Electrocore Inc Aktie (ECOR) Neueste Nachrichten
electroCore Stock (ECOR) Opinions on Recent Surge and Clinical Validation - Quiver Quantitative
Electrocore director Thomas J. Errico buys $59,852 in stock By Investing.com - Investing.com Australia
Electrocore director Thomas J. Errico buys $59,852 in stock - Investing.com
electroCore (ECOR) director boosts stake with 9,992-share open-market buy - Stock Titan
ElectroCore touts 30% growth outlook, VA opportunity at LD Micro Conference - MSN
ElectroCore CFO sells $19,500 in shares - Investing.com India
ElectroCore CFO sells $19,500 in shares By Investing.com - Investing.com Nigeria
electroCore (ECOR) CFO sells 3,000 shares to cover RSU taxes - Stock Titan
Electrocore Stock Price Forecast. Should You Buy ECOR? - StockInvest.us
electroCore Touts 30% Growth Outlook, VA Opportunity at LD Micro Conference - Yahoo Finance
Relay Therapeutics (RLAY) surges 16.4%: Is this an indication of further gains? - MSN
ECOR: Rapid growth, unique vagus nerve tech, and new partnerships drive future expansion - TradingView
electroCore (ECOR) Stock: Down -2.49%, Support Test at $5.96 2026-05-17Dealer Delta - Newser
ElectroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026 - marketscreener.com
electroCore (ECOR) Drops -5.29% — Key Support at $5.79 2026-05-15Imbalance Zone - Newser
electroCore (ECOR) Q1 2026 Earnings Transcript - AOL.com
Vagus Nerve Stimulators Market to Reach USD 1.86 Billion by 2033 - openPR.com
ECOR (NASDAQ) brokered sale notice: 45,000 shares valued $291,600 - Stock Titan
Quell device shows pain reduction in fibromyalgia study By Investing.com - Investing.com India
electroCore (ECOR) Reports Positive Fibromyalgia Trial Results - GuruFocus
Quell device shows pain reduction in fibromyalgia study - Investing.com
electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia - The Manila Times
electroCore Announces Publication in JAMA Highlighting the - GlobeNewswire
Wearable nerve stimulator eases fibromyalgia pain in JAMA trial - Stock Titan
Q2 Earnings Forecast for electroCore Issued By HC Wainwright - MarketBeat
Brokers Set Expectations for electroCore Q2 Earnings - MarketBeat
Number of shareholders of electroCore, Inc. – NASDAQ:ECOR - TradingView
Q1 Earnings Forecast for electroCore Issued By HC Wainwright - MarketBeat
ElectroCore reaffirms 2026 revenue guidance of ~30% growth while targeting deeper VA utilization - MSN
electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026 - Sahm
electroCore to present at LD Micro Invitational XVI on May 18, 2026, highlighting bioelectronic medicine advances - Pluang
electroCore to Present at LD Micro Invitational XVI Conference on May 18, 2026 - geneonline.com
Analysts Are Bullish on These Healthcare Stocks: Electrocore (ECOR), Warby Parker (WRBY) - The Globe and Mail
Maxim Group Maintains ElectroCore(ECOR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
electroCore (ECOR) Reports Strong Q1 Revenue Growth - GuruFocus
ECOR Forecasts 30% Revenue Growth for 2026 - GuruFocus
ElectroCore Q1 earnings preview - MSN
electroCore, Inc. (NASDAQ:ECOR) Q1 2026 Earnings Call Transcript - Insider Monkey
electroCore, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
electroCore Q1 2026 Earnings Call Transcript - MarketBeat
electroCore reports Q1 EPS (59c) vs. (47c) last year - TipRanks
electroCore Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Electrocore Q1 2026 revenue hits record high By Investing.com - Investing.com Canada
electroCore, Inc. (ECOR) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Veterans Affairs drives electroCore's record quarter; Truvaga enters UK - Stock Titan
electroCore (NASDAQ: ECOR) grows Q1 2026 sales but warns on going concern - Stock Titan
1.35%
2.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):